[Long-term therapeutic effect of Zenapax after renal transplantation].
OBJECTIVE
To determine whether there was any lingering effect after discontinuing Zenapax in renal transplantation and investigate there was any alternative immunity-regulating pathway of Zenapax other than IL-2/IL-2R.


METHODS
Thirty patients of renal transplantation were divided into 2 groups. One group of 15 received 2 dosages of induction therapy of Zenapax and another 15 regular immunosuppressive therapy. IL-2, IL-10, STAT5 and CD40L were tested followed up at 2 hours pre-transplantation, 1, 3 and 6 months post-transplantation.


RESULTS
The levels of IL-2 and STAT had no difference between the induction group and the control group. The level of IL-10 of induction group (59.4 +/- 7.7) ng/L was obviously higher than control group (36.8 +/- 8.4) ng/L at 3 months post-transplantation. CD40L level of induction group (10.6 +/- 3.6) was lower than control group (35.6 +/- 8.4) at 1 month post-transplantation.


CONCLUSIONS
Zenapax can reduce B-cell-mediated humoral immunity at 1 month post-transplantation through CD40L pathway.
Liu
Wei
W
Organ Transplantation Center, Renji Hospital, Shanghai Jiaotong University Medical School, Shanghai, China. nickylin@medmail.com.cn
Ling
Jian-yu
JY
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D023201:CD40 Ligand / Q000378:metabolism; D000077561:Daclizumab; D006085:Graft Survival; D006801:Humans; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D016030:Kidney Transplantation; D011184:Postoperative Period; D050799:STAT5 Transcription Factor / Q000378:metabolism; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508609:IL10 protein, human; C508594:IL2 protein, human; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D050799:STAT5 Transcription Factor; D016753:Interleukin-10; D023201:CD40 Ligand; D000077561:Daclizumab